loading...| Preferred Name |
Bazedoxifene |
|
| Synonyms |
BAZEDOXIFENE Bazedoxifene 1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl- TSE-424 WAY 140424 |
|
| Definitions |
An indole derivative and third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Upon administration, bazedoxifene specifically binds to estrogen receptors in responsive tissues, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it either promotes or suppresses the transcription of estrogen-regulated genes. Bazedoxifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the proliferative effects of estrogen-binding to ER-positive cells in these tissues. Bazedoxifene functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In bone, it decreases bone resorption and bone turnover and increases bone mineral density. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C73598 |
|
| CAS_Registry |
198481-32-2 |
|
| Chemical_Formula |
C30H34N2O3 |
|
| code |
C73598 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC |
|
| DEFINITION |
An indole derivative and third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Upon administration, bazedoxifene specifically binds to estrogen receptors in responsive tissues, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it either promotes or suppresses the transcription of estrogen-regulated genes. Bazedoxifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the proliferative effects of estrogen-binding to ER-positive cells in these tissues. Bazedoxifene functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In bone, it decreases bone resorption and bone turnover and increases bone mineral density. |
|
| Display_Name |
Bazedoxifene |
|
| FDA_UNII_Code |
Q16TT9C5BK |
|
| FULL_SYN |
BAZEDOXIFENE Bazedoxifene 1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl- TSE-424 WAY 140424 |
|
| Has_Salt_Form | ||
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Bazedoxifene |
|
| Legacy Concept Name |
Bazedoxifene |
|
| Maps_To |
Bazedoxifene |
|
| NCI_Drug_Dictionary_ID |
772911 |
|
| PDQ_Closed_Trial_Search_ID |
772911 |
|
| PDQ_Open_Trial_Search_ID |
772911 |
|
| Preferred_Name |
Bazedoxifene |
|
| prefixIRI |
Thesaurus:C73598 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2346970 |
|
| subClassOf |